Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

In the COMBI-v trial, patients with previously untreated BRAF Val600Glu or Val600Lys mutant unresectable or metastatic melanoma who were treated with the combination of dabrafenib and trametinib had significantly longer overall and progression-free survival than those treated with vemurafenib alone. Here, we present the effects of treatments on health-related quality of life (HRQoL), an exploratory endpoint in the COMBI-v study.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Lancet Oncol.

Title: The Lancet. Oncology

Publisher: Elsevier BV

ISSN (Electronic): 1474-5488

ISSN (Print): 1470-2045

Publication date (Electronic): Oct 2015

Volume: 16

Issue: 13

Affiliations

[1 ] Service de Dermatologie, Aix Marseille University, and Assistance Publique Hôpitaux de Marseille (APHM), University Hospital Timone, Marseille, France. Electronic address: jean-jacques.grob@ap-hm.fr.

[2 ] GlaxoSmithKline Oncology Research and Development, Collegeville, PA, USA.

[3 ] Przychodnia Lekarska Komed, Konin, Poland.

[4 ] Sheba Medical Center, Ramat Gan, Ramat, Israel.

[5 ] Department of Dermatology, Universität Zürich, Zurich, Switzerland.

[6 ] Oncology Division, Poznan University of Medical Sciences, Med-Polonia, Poznan, Poland.

[7 ] Moscow City Oncology Hospital #62, Stepanovskoye, Moscow, Russia.

[8 ] Swissmed Centrum Zdrowia and Gdansk Medical University, Gdansk, Poland.

[9 ] Centre Hospitalier Universitairede Reims-Hôpital Robert Debré, Reims, France.

[10 ] Istituto Oncologico Veneto Istituto Di Ricovero e Cura a Carattere Scientifico, Padua, Italy.

[11 ] Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland.

[12 ] N N Blokhin Russian Cancer Research Center, Moscow, Russia.

[13 ] Petrov Research Institute of Oncology, Saint Petersburg, Russia.

[14 ] University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium.

[15 ] Universitätsklinikum Schleswig-Holstein (UKSH), Department of Dermatology, Kiel, Germany.

[16 ] Melanoma Institute Australia, The University of Sydney and The Mater Hospital, Sydney, Australia.

[17 ] Mount Vernon Cancer Centre, Northwood, UK.

[18 ] University of California Los Angeles (UCLA) Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA.

[19 ] Massachusetts General Hospital Cancer Center, Boston, MA, USA.

[20 ] Department of Dermatology, University Hospital Essen, Essen, Germany.

[21 ] Gustave Roussy, Département de Médecine oncologique, Service de Dermatologie et Université Paris-Sud, Faculté de Médecine, Villejuif, France.

Article

Publisher Item ID: S1470-2045(15)00087-X

DOI: 10.1016/S1470-2045(15)00087-X

PubMed ID: 26433819

SO-VID: 509480ea-468e-4be3-bf26-e3449674b9ed

History

Data availability:

Comments

Comment on this article

scite_

Cited by 83

See all cited by

- Version 1